Pharmaceutical

ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases

GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.

Sep 16, 2024 - 04:00
ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases
GlobalData forecasts predict Enhertu will retain its dominant market position in the ADC treatment landscape.
Read the original article

Tags:

Previous Article

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC

Next Article

Express Scripts sues FTC and demands drug pricing report retraction

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Republicans want to crack down on pricey health regulations, but there are major loopholes

STAT+: Republicans want to crack down on pricey health ...

Jun 2, 2023

Opinion: Want to end historic health care strikes? Fix a broken, outdated reimbursement model

Opinion: Want to end historic health care strikes? Fix ...

Oct 26, 2023

PRO-1107 by ProfoundBio Suzhou for Non-Small Cell Lung ...

Apr 21, 2024